Influence of CINV prophylaxis (rolapitant, granisetron, dexamethasone) on quality of life in highly emetogenic chemotherapy protocols
Conditions
Interventions
Group 1: Patients on highly emetogenic chemotherapy protocol receiving the antiemesis triple rolapitant, granisetron, and dexamethasone for CINV prophylaxis
Sponsors
Universitätsmedizin Mainz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Patients who understand and can read German - Willingness to participate in the study: declaration of consent to participate (documented by signature) and data collection - Patients of the hematology/oncology wards of the III Medical Clinic of the University Medical Center Mainz (M3 605 3A - D) - Use of a highly emetogenic chemotherapy protocol as first cycle or repeat cycle, especially cisplatin-containing chemotherapy protocols and conditioning protocols in stem cell transplant patients.
Exclusion criteria
Exclusion criteria: - Lack of capacity to consent and/or ability of the patient to give consent - No willingness to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion of the FLIE questionnaire (after Lindley C) on days 1, 6 (and 13) of the chemotherapy protocol (influence of quality of life in intraindividual comparison, as well as comparison with data known from literature on aprepitant) | — |
Secondary
| Measure | Time frame |
|---|---|
| Review of assigned antiemetic prophylaxis via patient chart regarding correct assignment and proper administration, as well as review of whether additional antiemetics were given as on-demand medication during the course of the chemotherapy protocol | — |
Countries
Germany
Contacts
Public ContactTim Hippchen
Universitätsmedizin Mainz
Outcome results
None listed